COMPOSTOS ANTAGONISTAS DE PCSK9
COMPOSTOS ANTAGONISTAS DE PCSK9. São revelados compostos de Fórmula I, (I) ou um sal dos mesmos: onde A, B, D, X, R1, R2 e R8 são como definidos na presente invenção, cujos compostos têm propriedades para antagonizar PCSK9. Descreve-se também formulações farmacêuticas compreendendo os compostos de F...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | por |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | HAROLD B.WOOD SOBHANA BABU BOGA HUBERT B. JOSIEN ABBAS M. WALJI ELISABETTA BIANCHI DANILA BRANCA FA-XIANG DING SOOKHEE NICOLE HA CHENGWEI WU YUSHENG XIONG JIAN LIU ANILKUMAR G. NAIR ANGELA DAWN KEREKES THOMAS JOSEPH TUCKER LING TONG |
| description | COMPOSTOS ANTAGONISTAS DE PCSK9. São revelados compostos de Fórmula I, (I) ou um sal dos mesmos: onde A, B, D, X, R1, R2 e R8 são como definidos na presente invenção, cujos compostos têm propriedades para antagonizar PCSK9. Descreve-se também formulações farmacêuticas compreendendo os compostos de Fórmula I ou sais do mesmo, e métodos para tratar doenças cardiovasculares e condições relacionadas à atividade de PCSK9, por exemplo, aterosclerose, hipercolesterolemia, doença cardíaca coronária, síndrome metabólica, síndrome coronariana aguda, ou doenças cardiovasculares e condições cardiometabólicas relacionadas.
Disclosed are compounds of Formula I, or a salt thereof:where A, B, D, X, R1, R2 and R8 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_BR112020025274A8</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>BR112020025274A8</sourcerecordid><originalsourceid>FETCH-epo_espacenet_BR112020025274A83</originalsourceid><addsrcrecordid>eNrjZJB39vcN8A8O8Q9WcPQLcXT39_MMDnEMVnBxVQhwDva25GFgTUvMKU7lhdLcDKpuriHOHrqpBfnxqcUFicmpeakl8U5BhoZGBkYGBkamRuYmjhbGxKoDAOVNIz4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>COMPOSTOS ANTAGONISTAS DE PCSK9</title><source>esp@cenet</source><creator>HAROLD B.WOOD ; SOBHANA BABU BOGA ; HUBERT B. JOSIEN ; ABBAS M. WALJI ; ELISABETTA BIANCHI ; DANILA BRANCA ; FA-XIANG DING ; SOOKHEE NICOLE HA ; CHENGWEI WU ; YUSHENG XIONG ; JIAN LIU ; ANILKUMAR G. NAIR ; ANGELA DAWN KEREKES ; THOMAS JOSEPH TUCKER ; LING TONG</creator><creatorcontrib>HAROLD B.WOOD ; SOBHANA BABU BOGA ; HUBERT B. JOSIEN ; ABBAS M. WALJI ; ELISABETTA BIANCHI ; DANILA BRANCA ; FA-XIANG DING ; SOOKHEE NICOLE HA ; CHENGWEI WU ; YUSHENG XIONG ; JIAN LIU ; ANILKUMAR G. NAIR ; ANGELA DAWN KEREKES ; THOMAS JOSEPH TUCKER ; LING TONG</creatorcontrib><description>COMPOSTOS ANTAGONISTAS DE PCSK9. São revelados compostos de Fórmula I, (I) ou um sal dos mesmos: onde A, B, D, X, R1, R2 e R8 são como definidos na presente invenção, cujos compostos têm propriedades para antagonizar PCSK9. Descreve-se também formulações farmacêuticas compreendendo os compostos de Fórmula I ou sais do mesmo, e métodos para tratar doenças cardiovasculares e condições relacionadas à atividade de PCSK9, por exemplo, aterosclerose, hipercolesterolemia, doença cardíaca coronária, síndrome metabólica, síndrome coronariana aguda, ou doenças cardiovasculares e condições cardiometabólicas relacionadas.
Disclosed are compounds of Formula I, or a salt thereof:where A, B, D, X, R1, R2 and R8 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.</description><language>por</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230214&DB=EPODOC&CC=BR&NR=112020025274A8$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25562,76317</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230214&DB=EPODOC&CC=BR&NR=112020025274A8$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>HAROLD B.WOOD</creatorcontrib><creatorcontrib>SOBHANA BABU BOGA</creatorcontrib><creatorcontrib>HUBERT B. JOSIEN</creatorcontrib><creatorcontrib>ABBAS M. WALJI</creatorcontrib><creatorcontrib>ELISABETTA BIANCHI</creatorcontrib><creatorcontrib>DANILA BRANCA</creatorcontrib><creatorcontrib>FA-XIANG DING</creatorcontrib><creatorcontrib>SOOKHEE NICOLE HA</creatorcontrib><creatorcontrib>CHENGWEI WU</creatorcontrib><creatorcontrib>YUSHENG XIONG</creatorcontrib><creatorcontrib>JIAN LIU</creatorcontrib><creatorcontrib>ANILKUMAR G. NAIR</creatorcontrib><creatorcontrib>ANGELA DAWN KEREKES</creatorcontrib><creatorcontrib>THOMAS JOSEPH TUCKER</creatorcontrib><creatorcontrib>LING TONG</creatorcontrib><title>COMPOSTOS ANTAGONISTAS DE PCSK9</title><description>COMPOSTOS ANTAGONISTAS DE PCSK9. São revelados compostos de Fórmula I, (I) ou um sal dos mesmos: onde A, B, D, X, R1, R2 e R8 são como definidos na presente invenção, cujos compostos têm propriedades para antagonizar PCSK9. Descreve-se também formulações farmacêuticas compreendendo os compostos de Fórmula I ou sais do mesmo, e métodos para tratar doenças cardiovasculares e condições relacionadas à atividade de PCSK9, por exemplo, aterosclerose, hipercolesterolemia, doença cardíaca coronária, síndrome metabólica, síndrome coronariana aguda, ou doenças cardiovasculares e condições cardiometabólicas relacionadas.
Disclosed are compounds of Formula I, or a salt thereof:where A, B, D, X, R1, R2 and R8 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZJB39vcN8A8O8Q9WcPQLcXT39_MMDnEMVnBxVQhwDva25GFgTUvMKU7lhdLcDKpuriHOHrqpBfnxqcUFicmpeakl8U5BhoZGBkYGBkamRuYmjhbGxKoDAOVNIz4</recordid><startdate>20230214</startdate><enddate>20230214</enddate><creator>HAROLD B.WOOD</creator><creator>SOBHANA BABU BOGA</creator><creator>HUBERT B. JOSIEN</creator><creator>ABBAS M. WALJI</creator><creator>ELISABETTA BIANCHI</creator><creator>DANILA BRANCA</creator><creator>FA-XIANG DING</creator><creator>SOOKHEE NICOLE HA</creator><creator>CHENGWEI WU</creator><creator>YUSHENG XIONG</creator><creator>JIAN LIU</creator><creator>ANILKUMAR G. NAIR</creator><creator>ANGELA DAWN KEREKES</creator><creator>THOMAS JOSEPH TUCKER</creator><creator>LING TONG</creator><scope>EVB</scope></search><sort><creationdate>20230214</creationdate><title>COMPOSTOS ANTAGONISTAS DE PCSK9</title><author>HAROLD B.WOOD ; SOBHANA BABU BOGA ; HUBERT B. JOSIEN ; ABBAS M. WALJI ; ELISABETTA BIANCHI ; DANILA BRANCA ; FA-XIANG DING ; SOOKHEE NICOLE HA ; CHENGWEI WU ; YUSHENG XIONG ; JIAN LIU ; ANILKUMAR G. NAIR ; ANGELA DAWN KEREKES ; THOMAS JOSEPH TUCKER ; LING TONG</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_BR112020025274A83</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>por</language><creationdate>2023</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>HAROLD B.WOOD</creatorcontrib><creatorcontrib>SOBHANA BABU BOGA</creatorcontrib><creatorcontrib>HUBERT B. JOSIEN</creatorcontrib><creatorcontrib>ABBAS M. WALJI</creatorcontrib><creatorcontrib>ELISABETTA BIANCHI</creatorcontrib><creatorcontrib>DANILA BRANCA</creatorcontrib><creatorcontrib>FA-XIANG DING</creatorcontrib><creatorcontrib>SOOKHEE NICOLE HA</creatorcontrib><creatorcontrib>CHENGWEI WU</creatorcontrib><creatorcontrib>YUSHENG XIONG</creatorcontrib><creatorcontrib>JIAN LIU</creatorcontrib><creatorcontrib>ANILKUMAR G. NAIR</creatorcontrib><creatorcontrib>ANGELA DAWN KEREKES</creatorcontrib><creatorcontrib>THOMAS JOSEPH TUCKER</creatorcontrib><creatorcontrib>LING TONG</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>HAROLD B.WOOD</au><au>SOBHANA BABU BOGA</au><au>HUBERT B. JOSIEN</au><au>ABBAS M. WALJI</au><au>ELISABETTA BIANCHI</au><au>DANILA BRANCA</au><au>FA-XIANG DING</au><au>SOOKHEE NICOLE HA</au><au>CHENGWEI WU</au><au>YUSHENG XIONG</au><au>JIAN LIU</au><au>ANILKUMAR G. NAIR</au><au>ANGELA DAWN KEREKES</au><au>THOMAS JOSEPH TUCKER</au><au>LING TONG</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>COMPOSTOS ANTAGONISTAS DE PCSK9</title><date>2023-02-14</date><risdate>2023</risdate><abstract>COMPOSTOS ANTAGONISTAS DE PCSK9. São revelados compostos de Fórmula I, (I) ou um sal dos mesmos: onde A, B, D, X, R1, R2 e R8 são como definidos na presente invenção, cujos compostos têm propriedades para antagonizar PCSK9. Descreve-se também formulações farmacêuticas compreendendo os compostos de Fórmula I ou sais do mesmo, e métodos para tratar doenças cardiovasculares e condições relacionadas à atividade de PCSK9, por exemplo, aterosclerose, hipercolesterolemia, doença cardíaca coronária, síndrome metabólica, síndrome coronariana aguda, ou doenças cardiovasculares e condições cardiometabólicas relacionadas.
Disclosed are compounds of Formula I, or a salt thereof:where A, B, D, X, R1, R2 and R8 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | por |
| recordid | cdi_epo_espacenet_BR112020025274A8 |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS VINEGAR WINE |
| title | COMPOSTOS ANTAGONISTAS DE PCSK9 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T17%3A04%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=HAROLD%20B.WOOD&rft.date=2023-02-14&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EBR112020025274A8%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |